N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 2 ClinicalTrials.gov

A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy

Sponsor: argenx • ClinicalTrials.gov ID: NCT07287982

Registry updated: 2026-10-08
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

This study aims to find the correct dose of ARGX-119 for children with SMA. The study will also look at how safe the study drug is, how well it works, how it moves through the body, and how the immune system responds to it. The study consists of a double-blinded treatment period (DBTP) where participants will either receive ARGX-119 IV or placebo IV, in addition to disease-modifying therapy (DMT) for 24 weeks. Participants who complete the DBTP will enter the open-label active-treatment extension period (ATEP) during which all participants will receive ARGX-119 IV up to 100 weeks (approximately 2 years).

Interventions

  • ARGX-119 IV (Biological)
    Intravenous infusion of ARGX-119
  • Placebo IV (Other)
    Intravenous infusion of placebo

Eligibility criteria

Inclusion Criteria: * Is aged ≥5 to \<18 years when completing the informed consent process, defined as providing informed assent according to local regulations and having a parent or guardian sign the ICF, and can comply with protocol * requirements. * Has documented historical genetic diagnosis of 5q-SMA. * Currently receiving a stable SMA treatment regimen (nusinersen or risdiplam) and/or have a history of onasemnogene abeparvovec treatment * Must be able to walk at least 50 meters without walking aids in the 6MWT at screening Exclusion Criteria: * Known medical condition that would interfere with an accurate assessment of SMA, confound the results of the study, or put the participant at undue risk, as assessed by the investigator * Recent major surgery, except spinal fusion, within 3 months of screening or intends to have major surgery during the study * Current or previous administration of antimyostatin therapies in the past 6 months * Severe scoliosis (defined as curvature \>40°) and/or contractures at screening. o History of spinal fusion within 6 months before screening or planned during the study * Respiratory insufficiency, defined by the medical necessity for invasive or noninvasive ventilation for daytime treatment while awake. Ventilation used overnight or during daytime naps is acceptable.

Conditions

Spinal Muscular Atrophy (SMA)

Locations

  • Arkansas Children's Hospital — Little Rock, Arkansas, United States
  • Rady Childrens Hospital — San Diego, California, United States
  • Stanford University Medical Center — Stanford, California, United States
  • Connecticut Children's Medical Center — Hartford, Connecticut, United States
  • Rare Disease Research FL LLC — Kissimmee, Florida, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago — Chicago, Illinois, United States
  • University of Iowa Stead Family Children's Hospital — Iowa City, Iowa, United States
  • The Johns Hopkins Hospital — Baltimore, Maryland, United States
  • Boston Children's Hospital — Boston, Massachusetts, United States
  • The Curators of the University of Missouri on behalf of University of Missouri Health Care — Columbia, Missouri, United States
  • Columbia University Herbert Irving Comprehensive Cancer Center — New York, New York, United States
  • Rare Disease Research NC, LLC — Hillsborough, North Carolina, United States
  • Children's Hospital Philadelphia - Neurology — Philadelphia, Pennsylvania, United States
  • Neurology Rare Disease Center — Flower Mound, Texas, United States
  • Texas Children's Hospital — Houston, Texas, United States
  • Childrens Hospital of The Kings Daughters — Norfolk, Virginia, United States
  • Sydney Children's Hospital, Randwick — Randwick, New South Wales, Australia
  • Royal Children's Hospital — Parkville, Victoria, Australia
  • University of Calgary - Alberta Children's Hospital — Calgary, Alberta, Canada
  • BC Children's Hospital — Vancouver, British Columbia, Canada
  • The Hospital for Sick Children — Toronto, Ontario, Canada
  • Addenbrooke's Hospital — Cambridge, Cambridgeshire, United Kingdom
  • Great Ormond Street Hospital for Children — London, Greater London, United Kingdom
  • MDUK Oxford Neuromuscular Centre — Oxford, Oxfordshire, United Kingdom
  • Sheffield Children's Hospital — Sheffield, South Yorkshire, United Kingdom
  • Royal Hospital for Children — Glasgow, Strathclyde, United Kingdom
  • Birmingham Heartlands Hospital — Birmingham, West Midlands, United Kingdom
  • Leeds General Infirmary — Leeds, West Yorkshire, United Kingdom
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record